Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 9c; Offers FY23 EPS Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.84, $0.09 worse than the analyst estimate of $4.93. Revenue for the quarter came in at $972 million versus the consensus estimate of $969.02 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $18.15-$19.00, versus the consensus of $18.66.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance